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Troglitazone suppresses telomerase activity
independently of PPARg in estrogen-receptor
negative breast cancer cells
Fariborz Rashid-Kolvear1,2, Michael AS Taboski3,4,5, Johnny Nguyen1, Dong-Yu Wang2, Lea A Harrington3,4,6,
Susan J Done1,2,3*
Abstract
Background: Breast cancer is one the highest causes of female cancer death worldwide. Many standard
chemotherapeutic agents currently used to treat breast cancer are relatively non-specific and act on all rapidly
dividing cells. In recent years, more specific targeted therapies have been introduced. It is known that telomerase is
active in over 90% of breast cancer tumors but inactive in adjacent normal tissues. The prevalence of active
telomerase in breast cancer patients makes telomerase an attractive therapeutic target. Recent evidence suggests
that telomerase activity can be suppressed by peroxisome proliferator activated receptor gamma (PPARg). However,
its effect on telomerase regulation in breast cancer has not been investigated.
Methods: In this study, we investigated the effect of the PPARg ligand, troglitazone, on telomerase activity in the
MDA-MB-231 breast cancer cell line. Real time RT-PCR and telomerase activity assays were used to evaluate the
effect of troglitazone. MDA-MB-231 cells had PPARg expression silenced using shRNA interference.
Results: We demonstrated that troglitazone reduced the mRNA expression of hTERT and telomerase activity in the
MDA-MB-231 breast cancer cell line. Troglitazone reduced telomerase activity even in the absence of PPARg. In
agreement with this result, we found no correlation between PPARg and hTERT mRNA transcript levels in breast
cancer patients. Statistical significance was determined using Pearson correlation and the paired Student’s t test.
Conclusions: To our knowledge, this is the first time that the effect of troglitazone on telomerase activity in breast
cancer cells has been investigated. Our data suggest that troglitazone may be used as an anti-telomerase agent;
however, the mechanism underlying this inhibitory effect remains to be determined.
Background
Excluding non-melanoma skin cancers, breast cancer is
the most common malignancy in North American
women. In Canada, it is estimated that there will be 22
700 new cases of breast cancer and more than 5 400
women will die from this disease in 2009 [1].
Human breast carcinomas represent a heterogeneous
group of tumors with diverse behavior and responses to
therapy. Many standard chemotherapeutic agents cur-
rently used to treat breast cancer are relatively non-spe-
cific and act on all rapidly dividing cells. With the
recognition of different molecular subtypes of breast
cancer have come efforts to develop and introduce more
specifically targeted therapies such as Trastuzumab
(Herceptin) in HER2-positive breast cancers. Targeted
therapy has been used successfully for many years in the
treatment of breast cancer. Determination of estrogen
receptor (ER) status has been found to be an important
predictive and prognostic factor in the management of
breast cancer [2]. ER-positive breast cancer patients
have a number of available anti-estrogen treatment
options including tamoxifen and aromatase inhibitors.
However, few effective cancer prevention and treatment
strategies are available for ER-negative breast carcinoma
despite the urgent need to control their more aggressive
behavior. This has motivated considerable efforts toward
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finding new therapeutic approaches for the treatment of
this group of breast cancers.
Immortalization is a necessary step toward the malig-
nant transformation of normal human somatic cells,
which have intrinsic mechanisms that monitor cell divi-
sions and limit their life span. The terminal DNA at
chromosome ends, known as telomeres, progressively
shorten with each cell division and limit the replicative
life span of human cells in culture [3]. Most human can-
cer cells maintain their telomeres through activation of
telomerase (reviewed in [4]). In over 85% of human
tumors, and more than 90% of breast carcinomas, telo-
merase is active whereas in normal tissues telomerase is
active at low levels or is undetectable [5-7]. Telomerase
is a large ribonucleoprotein enzyme complex with an
estimated mass of approximately 670 kDa [8]. In vitro,
two components are minimally required for human telo-
merase activity; telomerase reverse transcriptase
(hTERT), the protein catalytic and often rate-limiting
subunit of telomerase, and the telomerase RNA (hTR),
an RNA template required for the synthesis of de novo
telomeric DNA [9]. The inhibition of telomerase limits
the growth of human cancer cells (reviewed in [4]), and
various anti-telomerase strategies are currently under
investigation in cancer patients.
Peroxisome proliferator activated receptors (PPARs)
are members of the nuclear hormone receptor super-
family, regulating gene expression via their ligand-acti-
vated transcriptional activity. There are three known
subtypes of PPARs; PPARa [10], PPARb/δ [11], and
PPARg [12]. PPARg plays an important role in lipid
metabolism, insulin sensitization, and cancers [13-15].
In addition to controlling the expression of many genes
involved in lipid metabolism, and insulin sensitization, it
has been found that PPARg functions as a tumor sup-
pressor in a variety of malignancies such as breast can-
cer, colon cancer, liposarcoma, ovarian cancer, and
prostate cancer (reviewed in [16]).
There are two classes of ligands for PPARg; natural
ligands and synthetic ligands. The natural ligands
include fatty acids and eicosanoids, components of oxi-
dized low-density lipoproteins, oxidized alkyl phospholi-
pids including lysophosphatidic acid and nitrolinoleic
acid (reviewed in [16]). The second group are members
of the thiazolidinedione (TZD) family including troglita-
zone, rosiglitazone, pioglitazone, and ciglitazone
(reviewed in [17]). TZDs are known as insulin sensiti-
zers and are used in the treatment of type II diabetes. It
has been shown that TZDs promote the differentiation
of various cell lines [18-22]. The TZDs troglitazone and
ciglitazone demonstrate antiproliferative activities in sev-
eral cancer models including breast cancer [23].
It has been suggested that PPARg is a tumor sup-
pressor gene in a variety of malignancies including
breast cancer (reviewed in [16]). Based on these obser-
vations, a phase II clinical trial was undertaken using
troglitazone in a group of patients with breast cancer
[24]. The results showed that PPARg activation had lit-
tle clinical benefit in the women selected for the trial.
However, tumour levels of PPARg were not measured.
Also, the patients had advanced breast cancer refrac-
tory to standard hormonal or chemotherapeutic agents,
which may have undermined the therapeutic effect of
troglitazone. The authors suggested that PPARg might
have greater impact as a preventative agent than a
therapeutic agent, as in experimental studies of colon
cancer.
PPARg regulates gene expression by forming a hetero-
dimer with retinoid X receptor (RXR) and binding to
peroxisome proliferator response elements (PPRE) on
target genes. Using the RXR ligand, Choi et al. demon-
strated inhibition of cell growth and telomerase activity
of breast cancer cells in vitro [25]. Interestingly, the
PPARg/RXR heterodimers can be activated by ligands
for either PPARg or RXR [26]. There is evidence that
PPARg can inhibit telomerase activity in some primary
cells [27-29]. The role of PPARg in modulating telomer-
ase activity in breast cancer cells has not been studied
and may have therapeutic potential. To determine if
PPARg regulates telomerase activity in breast cancer, we
examined the effect of the PPARg ligand, troglitazone,
on telomerase activity in breast cancer cell lines. We
showed that troglitazone reduced the mRNA expression
of hTERT and telomerase activity in the MDA-MB-231
breast cancer cell line. However, we found no correla-
tion between PPARg and hTERT mRNA transcript
levels in breast cancer patients indicating this reduction
was independent from PPARg.
Methods
Materials
MDA-MB-231, MCF-7, and T47D cell lines were
obtained from American Type Culture Collection
(ATCC) (Manassas, VA). Troglitazone and GW9662
were purchased from Sigma (Sigma-Aldrich, St Louis,
MO) and BADGE from Cayman (Cayman, Ann Arbor,
MI). Antibodies against Maspin and PPARg were pur-
chased from BD Biosciences (Mississauga, ON) and
Santa Cruz Biotechnology (Santa Cruz, CA) respectively.
TaqMan specific primers for PPARg, hTERT, K19, Muc-
1 were obtained from Applied Biosystems (Branchburg,
New Jersey). Cell culture media was from the Ontario
Cancer Institute (OCI) (Princess Margaret Hospital,
Toronto, ON).
Cell culture
MDA-MB 231 cells were cultured in alpha MEM med-
ium (aMEM) (Princess Margaret Hospital, ON)
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supplemented with 10% v/v fetal bovine serum
(HyClone, Logan, UT) at 37°C in a humidified atmo-
sphere with 5% CO2 for 24 hours, then treated with
either troglitazone (dissolved in DMSO) or an equal
volume of DMSO (Sigma-Alderich Life Science, Saint
Louis, MO) and incubated for various timepoints.
Cell toxicity and cell viability assay
Cell toxicity was measured using the CellTiter96 nonra-
dioactive proliferation assay kit (Promega, Madison).
Briefly, cells were seeded in 96-well plates at a density
of 7 × 103 cells/well and treated with the indicated con-
centrations of troglitazone. At the end of each time
point, cells were incubated with 20 μl MTS/PMS solu-
tion for a further 3 hours in a humidified environment.
The toxicity of troglitazone was determined by measur-
ing the formazan produced by proliferating cells at 490
nm on a Tecan SpectraFluor Plus Plate Reader (MTX
Lab Systems, Inc, Vienna, VA).
The cell viability was measured by automated Vi-
CELL, which uses the trypan blue dye exclusion method
(Beckman Coulter, Brussels, Belgium).
Western blot analyzing
Total protein was extracted from cells using CytoBus-
ter™ Protein Extraction Reagent (Novagen, Darmstadt,
Germany) containing protease phosphatase inhibitors.
Protein separation was performed on 4% to 12% w/v
SDS-NuPage gradient gel (Invitrogen Life Technologies).
Western blot analysis was performed using standard
methods. Images were analyzed and quantified using
Image J software [Research Services Branch (RSB) of the
National Institute of Mental Health (NIMH), National
Institutes of Health (NIH), USA, http://rsb.info.nih.gov/
nih-image].
Real-time RT-PCR
Total RNA was extracted using RNeasy® plus kit (Qia-
gen, Mississauga, ON), and used for real-time reverse
transcription (RT) in a two-step procedure. In the first
step, an aliquot of 2 μg total RNA from each sample
was reverse transcribed to cDNA using TaqMan®
Reverse Transcription Reagents (Applied Biosystems,
Branchburg, New Jersey). In the second step, 100 ng
cDNA was used for PCR using TaqMan® Universal PCR
Master Mix (Applied Biosystems, Branchburg, New Jer-
sey) in a 384-well plate according to the manufacturer’s
instructions. We used TaqMan specific primers for
hTERT, PPARg, and GAPDH in our experiments pur-
chased from Applied Biosystems (Warrington, UK). The
real-time quantitative PCR and analysis were carried out
using the ABI Prism 7900 HT Sequence Detection sys-
tem (Foster City, CA).
Stable shRNA mediated repression of PPARg in MDA-MB-
231 cells
Human PPARg expression in wild type MDA-MB-231
breast cancer cells was silenced by shRNA interference.
Four lentiviral gene transfer vectors expressing shRNA
against PPARg (NM_138712) were purchased from
Open Biosystems (Huntsville, AL, USA); shPPARg-70,
shPPARg-72, shPPARg-73, and shPPARg-74. An adopted
Qiagen non-silencing control shRNA sequence
(TTCTCCGAACGTGTCACGT) that was not comple-
mentary to any human gene was used as a control
shRNA (generous gift from Dr. M.S. Tsao, University of
Toronto). Lentiviruses were prepared in 293 cells fol-
lowed by infection into MDA-MB-231 cells. Cells were
selected using 0.5 μg/ml puromycin as previously
described [30,31] and subjected to real-time RT-PCR to
test the mRNA expression level of PPARg in the
infected MDA-MB-231 cells.
Telomeric repeat amplification protocol (TRAP) assay
For TRAP assays, cells were lysed in 4-5 volumes of ice-
cold CHAPS buffer (0.5% w/v CHAPS, 10 mM Tris-Cl
pH 7.5, 10% v/v glycerol, 1 mM MgCl2, 5 mM b-mer-
captoethanol, EDTA-free Complete protease inhibitor
(Roche, Switzerland) and 400 U Roche RNase Inhibitor
(Roche). TRAP assay reactions were performed using
the radioactive method of the TRAPeze kit (Millipore,
Billerica, MA, USA) with some modifications which fol-
low. The telomerase extension step was performed in
the absence of Taq Polymerase in the reactions. After
the telomerase extension, the reactions were heated to
94°C for 2 minutes, followed by the addition of 2 units
of Taq polymerase (NEB, Ipswich, MA, USA) and PCR
amplification. PCR conditions were 25 cycles of 94°C for
30 seconds, 50°C for 30 seconds, and 72°C for 90 sec-
onds. Half of the 50 μl reaction was loaded on a 10% w/
v non-denaturing acrylamide: bis-acrylamide (19:1) gel
in 0.6X TBE buffer. The gel was dried and exposed to a
phosphorimager screen and scanned using a Typhoon
Trio Imager (GE Healthcare, United Kingdom). Protein
titrations of 500 ng and 250 ng were performed in each
sample to ensure TRAP reaction products exhibited a
semi-linear response. CHAPS lysis buffer and a positive
telomerase activity control HeLa cell lysate (equivalent
of 500 cells) were used as negative and positive controls
respectively. The TRAP assay includes a 36 bp PCR
amplification product that serves as an internal control
that monitors PCR inhibition in each reaction.
Microarray dataset and analysis
The Netherlands Cancer Institute (NKI) dataset was used
to compare the expression of PPARg and hTERT [32].
The NKI dataset has published genome-wide gene
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expression microarray data from 295 breast cancer sam-
ples collected between 1984 and 1995. The paired expres-
sion data of PPARg (Probe ID: 17022) and hTERT (Probe
ID: 1809) for 294 patients were analyzed by Pearson cor-
relation. For one patient, PPARg data was not available.
Statistical analysis
All numerical data were expressed as median values ±
SD. Statistical significance was determined by perform-
ing Pearson correlation or the paired Student’s t test.
Results
Evaluating the expression of PPARg in different breast
cancer cell lines
Three different breast cancer cell lines; MDA-MB-231,
MCF-7, and T47D were analyzed for PPARg expression.
Real-time RT-PCR showed that mRNA expression of
PPARg was higher in MDA-MB-231 cells compared to
the other two cell lines (Figure 1A). In agreement with
this result, we found that the expression of PPARg pro-
tein was higher in MDA-MB-231 than the two other
cell lines (Figure 1B).
Determining the mRNA expression level of hTERT and
telomerase activity in MDA-MB-231 cells
Results from real-time RT-PCR indicated that all three cell
lines expressed hTERT mRNA (Figure 1C), and the TRAP
assay confirmed that telomerase was active in these cell
lines (Figure 1D). Based on the level of PPARg mRNA and
protein expression, and the presence of hTERT mRNA
and telomerase activity, the MDA-MB-231 cell line was
selected as an in vitro model for this study.
Troglitazone reduces telomerase activity in a dose and
time dependent manner
MDA-MB-231 cells were cultured in growth medium
with increasing concentrations of troglitazone or
equivalent volumes of DMSO for 24 hours. Visible
Figure 1 The expression of PPARg, hTERT and telomerase activity in several breast cancer cell lines. A) Total RNA was prepared from
MDA-MB-231, MCF-7, and T47D cells. Using real-time RT-PCR, the mRNA expression of PPARg was measured and MDA-MB-231 cells had the
highest expression of PPARg mRNA. B) Protein lysates were prepared from the breast cancer cell lines and analyzed via western blotting to
examine the level of PPARg protein. MDA-MB-231 cells express more PPARg protein than MCF-7 and T47D cells in this representative western
blot. C) Total RNA was used to examine the mRNA expression level of hTERT in MDA-MB-231, MCF-7, and T47D cells by real-time RT-PCR. Values
express the relative quantity of the genes to the level of mRNA expression of GAPDH. D) Telomerase activity was measured from protein lysates
(500 and 250 ng respectively) in MDA-MB-231, MCF-7, and T47D cell lines. I.C. the internal PCR amplification control. CHAPS, lysis buffer only as a
negative control. HeLa, 500 cell equivalent lysate as a positive control.
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inhibition of telomerase activity was observed at a tro-
glitazone concentration of 20 μM, which increased at
40 μM and 80 μM of troglitazone (Figure 2A). Cells
were treated with 20 μM troglitazone or an equivalent
volume of DMSO for 24 or 48 hours. Cells were then
harvested and telomerase activity was measured by the
TRAP assay. The inhibition of telomerase activity
using 20 μM of troglitazone at 48 hours was greater
than at 24 hours. These results suggest that telomerase
inhibition by troglitazone is both dose and time depen-
dent, and that treatment of 20 μM of troglitazone for
24 hours was minimally sufficient for telomerase inhi-
bition (Figure 2B).
Troglitazone suppresses hTERT transcription
To test if lower concentrations of troglitazone reduce
the level of hTERT mRNA, MDA-MB-231 cells were
treated with concentrations of troglitazone less than 20
μM for 24 hours and the mRNA expression of hTERT
was determined by real-time RT-PCR. Troglitazone
exhibited a significant dose dependent reduction in the
expression of hTERT mRNA compared to control at a
concentration of 20 μM (P < 0.05) (Figure 2C). This
result suggests that troglitazone suppressed telomerase
activity by reducing the level of hTERT mRNA. How-
ever, cells treated for 12 hours with 20 μM troglitazone
did not show significant changes in hTERT mRNA
Figure 2 Troglitazone suppresses the activity of telomerase in a dose and time dependent manner. A) Protein lysates (500 and 250 ng
respectively) from MDA-MB-231 cells with no treatment (WT), treated with various concentrations of troglitazone (Tro) or the equal volume of
DMSO for 24 hours were examined for telomerase activity by the TRAP assay. B) MDA-MB-231 cells were treated with 20 μM of troglitazone (Tro
20 μM) and the equal volume of DMSO for 24 and 48 hours. Protein lysate (500 and 250 ng respectively) from non-treated cells (WT), Tro 20 μM,
and DMSO was used for the TRAP assay. A and B) I.C., the internal PCR amplification control. CHAPS, lysis buffer only as a negative control. HeLa,
500 cell equivalent lysate as a positive control. C) Total RNA was collected from DMSO and troglitazone treated cells for 24 hours and the mRNA
expression level was measured by real-time RT-PCR. Data were normalized against the DMSO treated group (control) in the respective treatment
condition. D) Total RNA from MDA-MB-231 cells treated with DMSO and 20 μM of troglitazone (Tro 20 μM) for 12 hours was extracted and the
mRNA expression of hTERT was analyzed by real-time RT-PCR. Values express the relative quantity of hTERT to GAPDH. The final percentage of
DMSO did not exceed 0.1% v/v. C and D) results shown are expressed as mean ± SD and are representative of at least three independent
experiments. * p < 0.05.
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compared to controls (Figure 2D). Our results indicate
that the minimum concentration and time to observe
the effect of troglitazone on hTERT transcription and
telomerase activity is 20 μM for 24 hours.
Reduction in telomerase activity is independent of the
transcriptional role of PPARg
To assess the involvement of PPARg in the reduction of
telomerase activity, MDA-MB-231 cells were exposed to
two different PPARg antagonists, 10 μM GW9662 [33]
and 100 μM of BADGE [34], for 24 hours prior to tro-
glitazone treatment. Results from real-time RT-PCR
showed that addition of either GW9662 or BADGE did
not abrogate the suppressive effect of troglitazone on
hTERT gene expression (Figure 3A).
Furthermore, we knocked down the expression of
PPARg using shRNA interference using lentiviral infec-
tion. Results from real-time RT-PCR showed that the
expression of PPARg mRNA in knocked-down cells was
significantly decreased compared to wild type and
scrambled shRNA infected cells (Figure 3B). With
PPARg expression significantly decreased, we examined
the telomerase activity in the MDA-MB-231 cells and
found that there were no significant changes in telomer-
ase activity in knocked-down cells compared to wild
type MDA-MB-231 cells (Figure 3C).
Figure 3 The suppressive role of troglitazone on telomerase is independent from PPARg. A) MDA-MB-231 cells were exposed to either 10
μM GW9662 or 100 μM BADGE for 24 hours. Cells then were treated with 20 μM troglitazone in the presence of GW9662 or BADGE for another
24 hours. At the end of the incubation time, the expression level of hTERT was determined by real time RT-PCR. Values are expressed as the
percentage of vehicle-treated controls (DMSO) in the respective treatment condition. Results shown are as mean ± SD and are representative of
three independent experiments. B) Utilizing shRNA interference, the expression of PPARg was inhibited with four different shRNA oligos (71, 72,
73, and 74) in the MDA-MB-231 cell line. To assess the specificity of shRNA oligos against PPARg , MDA-MB-231 cells were transfected with
scrambled oligo as a control. The mRNA level of PPARg was examined by real-time RT-PCR. WT, non-infected cells; SCR, scrambled oligo; 71-74
shRNA oligos. C) The TRAP assay was used to examine the activity of telomerase in MDA-MB-231 cells in the absence of PPARg (Oligo 71, 72, 73,
74) compared to non-infected MDA-MB-231 cells (WT) and cells transfected with a scrambled oligo which acted as non-silencing control shRNA
sequence (SCR). (500 and 250 ng of cell lysate, respectively. D) MDA-MB-231 cells carrying silenced PPARg by shRNA were treated with 20 μM
troglitazone or the equal volume of DMSO for 24 hours and telomerase activity was measured using the TRAP assay (500 and 250 ng of cell
lysate, respectively). C and D) I.C., the internal PCR amplification control. CHAPS, lysis buffer only as a negative control. HeLa, 500 cell equivalent
lysate as a positive control. Result shown is representative of two independent experiments.
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To examine the effect of troglitazone on telomerase
activity in the absence of PPARg, wild type and PPARg
knocked-down MDA-MB-231 cells were treated with 20
μM troglitazone for 24 hours. Our data showed that tro-
glitazone was able to suppress telomerase activity in the
absence of PPARg transcription (Figure 3D).
The cell toxicity effect of troglitazone
To determine the non-toxic concentration of troglita-
zone for cell treatment in our study, we measured the
IC50 for troglitazone using the CellTiter96 non-radioac-
tive proliferation assay kit. This assay measures the
activity of dehydrogenase found in metabolically active
cells. Dehydrogenase, a mitochondrial enzyme, reduces
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt)
chemically into formazan [35]. Since the production of
formazan is proportional to the activation of this
enzyme in viable cells, the intensity of the produced
color is an indicator of cell viability. The MTS result
showed that the IC50 of troglitazone after 24 and 48
hours exposure was 190 μM (Figure 4A). Therefore, 20
μM of troglitazone for 24 hours is not toxic to MDA-
MB-231 cells.
Troglitazone does not induce apoptosis
It has been shown that PPARg ligands induce pro-
grammed cell death (apoptosis) (for review see [36]).
First, we examined the effect of troglitazone on cell via-
bility using the trypan blue dye exclusion method. Cells
treated with troglitazone showed a slight reduction in
cell viability compared to controls (Figure 4B), however,
this reduction was not statistically significant. We also
studied the effect of troglitazone on caspase-3, the main
apoptosis regulator. We found that the protein level of
caspase-3 remained unchanged in response to troglita-
zone treatment (Figure 4C). Furthermore, we examined
the protein levels of poly (ADP-ribose) polymerase
Figure 4 Troglitazone does not cause cell toxicity and does not induce apoptosis in MDA-MB-231 cells. A) MDA-MB-231 cells were
treated with various concentrations of troglitazone (0, 10, 20, 50, 100, 250, 500, 1000 μM) for 24 or 48 hours and cell toxicity was determined by
the MTS assay. All data were normalized against the DMSO treated control group in the respective treatment. B) Cells were exposed to 20 μM
troglitazone for 3 days and cell viability was measured using automated Vi-CELL. Values expressed as percent survival of DMSO treated controls.
Data were collected from three experiments performed in triplicate. WT, DMSO; T20, 20 μM troglitazone. C) Equal amounts of MDA-MB-231 cell
lysate from DMSO and treated cells with 20 μM troglitazone (Tro 20 μM) for 24 hours were subjected to western blot analysis to determine the
protein levels of caspase-3 and PARP. No differences were found between control and troglitazone treated cells. The western blots shown are
representative of three separate experiments.
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(PARP), a protein which undergoes caspase-3 mediated
cleavage during apoptosis and produces an 89 kDa frag-
ment. In agreement with the caspase-3 results, we did
not observe a reduction of PARP protein levels in trogli-
tazone treated cells compared to DMSO treated cells
(Figure 4C). These results confirm that troglitazone at
20 μM for 24 hours does not induce apoptosis and is
not toxic to the cells.
Troglitazone does not induce differentiation of MDA-MB-
231 within 24 hours
Accumulating evidence indicates that PPARg promotes
cell differentiation following activation by its ligand
[18-22] and since telomerase is not active in differen-
tiated cells [37,38], we wondered if the inhibition of tel-
omerase by troglitazone is the result of cell
differentiation. MDA-MB-231 cells were treated with 20
μM of troglitazone for 24 hours and the expression of
maspin was examined as a marker for differentiated
breast epithelial cells [39]. As shown in Figure 5A, tro-
glitazone did not increase the protein level of maspin,
indicating that treated cells do not exhibit significant
differentiation at 24 hours post-treatment. We also mea-
sured the expression of two genes associated with breast
malignancy, Keratin 19 (K19) and mucin-1 (Muc-1) as
previously described [19]. Real-time RT-PCR showed
the expression of these two genes was unchanged in tro-
glitazone treated cells (Figure 5B and 5C).
The expression of hTERT is not correlated with the
expression of PPARg in clinical samples
Published NKI data from 294 young patients with pri-
mary invasive breast cancers was used to compare the
expression of PPARg and hTERT [32,40]. We found that
the expression of PPARg and hTERT in this set of sam-
ples was 44% and 62% respectively (data not shown).
Our results show that there is no correlation between
the level of PPARg expression and hTERT expression (r
= -0.152) in these samples (Figure 6A). Since MDA-MB-
231 cells are estrogen receptor negative [41], we com-
pared the expression of PPARg and hTERT genes in
estrogen receptor-negative (N = 69) and estrogen recep-
tor-positive (N = 225) tumor samples and no correlation
was observed between the two genes in either estrogen
receptor-positive (r = -0.156) (Figure 6B) or estrogen
receptor-negative (r = -0.08) (Figure 6C) tumors.
Discussion
Breast cancer, the most common malignancy in women,
is a heterogeneous disease currently treated with sur-
gery, chemotherapy and radiation. All of these methods
treat the cancer, but affect healthy tissue as well. There
is a desperate need for new therapies to treat breast
cancer as many cases fail to respond to current
chemotherapeutic agents. Targeted cancer therapies
focus on specific molecules that influence the growth
and spread of cancer cells. ER was the first protein that
was successfully targeted. More recently trastuzumab
(Herceptin) has been introduced for the treatment of
women with HER2 positive breast cancers. Inhibition of
telomerase has been found to limit the growth of
human cancer cells (reviewed in [4]). Telomerase is
active in 90% of breast cancers [5-7], which make it a
Figure 5 Troglitazone does not induce cell differentiation.
MDA-MB-231 cells were treated with 20 μM of troglitazone (Tro 20
μM) or the equal volume of DMSO for 24 hours. A) Representative
western blot showing the effect of 20 μM of troglitazone on the
protein level of maspin. Western blots of total protein were probed
with anti-maspin antibodies and then reprobed with anti-GAPDH to
confirm equal loading. B and C) Total RNA from treated and control
cells was used to examine the expression level of B) Mucin-1 (Muc-
1) and C) Keratin 19 (K19) by real-time RT-PCR. Values express the
relative quantity of the genes to the level of mRNA expression of
GAPDH. Data shown is representative of three separate experiments.
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promising potential target for breast cancer treatment.
There is some evidence indicating that PPARg may play
a critical role in this process [27-29,42]. The objective of
this study was to investigate the effect of troglitazone on
telomerase as a potential novel therapeutic approach
that could be used to treat breast cancer. To our knowl-
edge, this is the first time that the effect of troglitazone
on telomerase activity in breast cancer has been studied.
We studied three human breast cancer cell lines;
MDA-MB-231, MCF-7, and T47D. MDA-MB-231 is
estrogen receptor negative [41], EGF responsive and
IGF-I non-responsive. MCF7 is estrogen receptor posi-
tive [41], EGF non-responsive and IGF-I responsive and
T47D is estrogen receptor positive, EGF responsive and
IGF-I non-responsive [43]. Real-time RT-PCR data
showed the expression of PPARg mRNA was higher in
MDA-MB-231 cells compared to MCF-7 and T47D.
Western blot analysis confirmed that all three cell lines
express detectable amounts of PPARg protein in agree-
ment with the results from other investigators [44,45].
We also validated the expression of hTERT and telo-
merase activity in these cell lines. Real-time RT-PCR
showed that all three cell lines express hTERT mRNA.
This data has been confirmed by the TRAP assay, indi-
cating that telomerase is active in all three cell lines.
It has been shown that 17b-estradiol (E2) up-regulates
telomerase activity in ER-positive breast cancer models
both in vivo and in vitro [46-48]. Using ER-positive
MCF-7 breast cancer cells, it has been found that the
activation of telomerase is accompanied by up-regula-
tion of hTERT mRNA [47,48]. Evidence indicates that
estrogen activates hTERT directly by binding to estro-
gen response elements (EREs) found in the promoter of
hTERT and indirectly through activation of c-Myc
expression in MCF-7 cells [47,48]. However, a similar
result in ER-negative cells was not observed, suggesting
a regulatory role for estrogen that is limited to ER-posi-
tive cells [47,48].
To study the effect of PPARg on telomerase activity,
the MDA-MB-231 cell line was chosen as an estrogen
receptor negative model because of the presence of
active telomerase and high expression of PPARg protein.
Using the TRAP assay, we showed that troglitazone sup-
presses telomerase activity specifically. The presence of
an internal control in the TRAP assay indicated that the
suppression of telomerase activity was not due to inhibi-
tion of PCR amplification.
We also found that hTERT mRNA levels were signifi-
cantly reduced by troglitazone. Our result showed that
20 μM of troglitazone was the minimum concentration
able to suppress telomerase activity after 24 hours. We
also found that troglitazone at this concentration was
not toxic to the cells indicating that the inhibition of
Figure 6 The expression of hTERT is independent from PPARg.
Genome-wide gene expression microarray data for 294 patients
with early breast cancers from the NKI published dataset was used
to measure the correlation between hTERT and PPARg expression in
A) all 294 tumor samples with early breast cancers (r = -0.1522)(p =
0.0089), B) 69 estrogen receptor negative tumors (r = -0.0807)(p =
0.5), and C) 225 estrogen receptor-positive tumors (r = -0.1563)(p =
0.0189).
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telomerase by troglitazone is not a consequence of cell
toxicity.
There is accumulating published data indicating that
troglitazone can act independently from PPARg [17,49]).
In addition, it has been shown recently that thiazolidine
derivatives unable to activate PPARg have an antiproli-
ferative effect in both hormone-dependent and hormone
independent breast cancer cell lines [50].To study the
role of PPARg in modulating the expression of hTERT
and telomerase activity, we studied the effects that two
structurally different PPARg antagonists, BADGE and
GW9662 have upon troglitazone inhibition of hTERT
expression. We found that neither BADGE nor
GW9662 were able to prevent the suppressive effect of
troglitazone on hTERT expression. This finding was
confirmed using shRNA silencing of PPARg. We showed
that troglitazone suppresses telomerase even in the
absence of PPARg mRNA expression. This result indi-
cates that the effect of troglitazone on telomerase activ-
ity is independent from PPARg. There is some evidence
showing that activated PPARg abolishes telomerase
activity [27-29,42]. It is noteworthy that none of these
groups used MDA-MB-231 cells as their models. More-
over, none of them used troglitazone as the ligand for
PPARg. Recently, using pancreatic cancer cell lines,
Kondoh et al. showed that 15-deoxy-Δ12,14 prostaglan-
din J2 (15d-PGJ2), a natural ligand for PPARg, sup-
presses the expression of hTERT by blocking ER
functions [51]. However, this group did not demonstrate
whether this suppression is mediated through PPARg
activation. Although the underlying mechanism for
these differences remains to be discovered, it may reflect
differences in experimental models and approaches such
as cell type, particular ligand, duration of treatment, and
dosage.
To examine whether the suppression of telomerase is
the result of apoptosis induction, we investigated the
effect of troglitazone on cell viability and the protein
levels of caspase-3 and PARP as apoptosis markers.
Although it has been shown that troglitazone induces
apoptosis in different cancer cell lines by different
mechanisms [52-55], our result showed that troglitazone
does not induce apoptosis in MDA-MB-231 cells at this
concentration. It is noteworthy that these groups used a
higher concentration of troglitazone. Published data
from other groups indicates that a low concentration of
troglitazone cannot promote apoptosis. Elstner et al.
showed that 10 μM troglitazone does not induce apop-
tosis in the MCF-7 cell line after 4 days incubation [56].
In agreement with this study, Ohta et al. demonstrated
that although 10 μM troglitazone can induce DNA frag-
mentation in BHP18-21, a thyroid papillary carcinoma
cell line, it was not able to change the expression level
of bcl-2 and bax genes. Interestingly, 10 μM troglitazone
induced DNA fragmentation when BHP18-21 cells were
cultured in 0.1% v/v fetal calf serum (FCS). Conversely,
under 10% v/v FCS conditions, more than 100 μM tro-
glitazone was required to induce DNA fragmentation
[57]. In agreement with this result, we found that 20
μM troglitazone induces apoptosis in our cell culture
model in 0.1% v/v FBS media after 24 hours incubation
(data not shown). The differences in troglitazone con-
centration, culture conditions, and cell types may
explain these differences. Importantly, all these groups
showed that regardless of the concentration of troglita-
zone used, the induction of apoptosis was independent
from PPARg activity [52-57]. Since the promotion of
apoptosis was not observed in our cell model, it suggests
that the suppression of hTERT and its telomerase activ-
ity by troglitazone is not due to apoptosis activation.
Although PPARg can promote cell differentiation
[18-22], this effect has not been observed in all studies
[56]. Since differentiated cells do not generally possess
detectable telomerase activity [37,38], we investigated if
telomerase suppression in our study was the result of
cell differentiation. MDA-MB-231 cells were exposed to
various concentrations of troglitazone for different time
periods. We examined the expression of three different
markers associated with breast cancer. It has been
shown that the mRNA expression of maspin is
decreased in malignant breast cells compared to normal
breast epithelial cells [39]. In contrast, K19 and Muc-1
are associated with more malignant breast epithelial
cells [19]. Our results showed that troglitazone was not
able to change the expression of these genes within 24
hours, indicating that treated cells had not become dif-
ferentiated during this time. Furthermore, by increasing
the concentration of troglitazone, we did not observe
any signs of cell differentiation but we observed cell
toxicity and apoptosis. This result suggests that troglita-
zone at low concentrations inhibits telomerase activity
independently from cell differentiation, and is an effect
that cannot be ascribed to cell toxicity or apoptosis.
There is a significant correlation between hTERT
mRNA and telomerase activity in human breast carci-
noma tissue [58]. To compare our findings with what
has been observed in clinical samples, we analyzed the
expression of PPARg and hTERT from genome-wide
gene expression microarray data for 294 patients
[32,40]. We found no correlation between these two
genes (r = -0.152). Furthermore, since the MDA-MB-
231 cell line is an estrogen receptor negative cell line,
we compared the expression of hTERT and PPARg in
estrogen receptor (ER) negative patients. No correlation
was found between the expression of hTERT and
PPARg (r = -0.08) in this group of patients. In agree-
ment with our in vitro model, this result suggests that
telomerase inhibition by PPARg ligands is independent
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from PPARg transcriptional activity and is effected by an
unknown mechanism.
Conclusions
To our knowledge this is the first time that the effect
of troglitazone on telomerase activity has been studied
in human breast cancer. We showed that the expres-
sion of hTERT and PPARg are two independent events
and troglitazone reduces the activity of telomerase by
recruiting other pathway(s) rather than PPARg activity.
Our study shows although the mechanism underlying
this suppression remains unclear, and may be indirect,
troglitazone can be considered as an anti-telomerase
agent in estrogen-receptor negative breast cancer cells.
In addition, based on data from our studies as well as
others, we suggest that the role of troglitazone, and
probably the other members of TZD family, should be
revisited beyond their original role merely as PPARg
ligands.
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